James Johnston, DO
Ophthalmology · Tallmadge, OHNPI 1316940174
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,868 of the $14,368 with a category attached, or 82.6%. It is spread thinly across 46 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. Among ophthalmology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 353 payments — averaging $40.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$3K
- Alcon$3K
- Bausch & Lomb Americas Inc.$1K
- Oyster Point Pharma, Inc.$821
- AbbVie$803
- NEW World Medical,inc.$674
- plus $5K from 40 others
What the payments were for
- Speaking & faculty fees$2,50017%
- Food & beverage$11,86883%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENVISTA$2,500
- TRULIGN TORIC$2,500
- CRYSTALENS$2,500
- MIEBO$629
- XIIDRA$504
- VYZULTA$503
- ARGOS$409
- Clareon$395
- Clareon PanOptix Pro$269
- LUMIGAN$250
- XEN GLAUCOMA TREATMENT SYSTEM$249
- XDEMVY$246
- Kahook Dual Blade$246
- Streamline Surgical System$246
- Ahmed Glaucoma Valve$246
- DURYSTA$246
- TEPEZZA$244
- Rocklatan$233
- Oxervate$227
- TYRVAYA$223
How this compares
$14,368 in reported general payments places this provider in the 90th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 74 | $94,739 |
| LumiganBimatoprost | 74 | $40,882 |
| MieboPerfluorohexyloctane/Pf | 33 | $34,043 |
| Cyclosporine | 33 | $28,913 |
| XiidraLifitegrast | 18 | $27,789 |
| RocklatanNetarsudil Mesylat/Latanoprost | 42 | $26,190 |
| VyzultaLatanoprostene Bunod | 37 | $25,042 |
| CequaCyclosporine | 26 | $23,544 |
| Brimonidine Tartrate | 240 | $19,990 |
| RhopressaNetarsudil Mesylate | 20 | $15,778 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 15 | $14,096 |
| Latanoprost | 622 | $8,042 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 24 | $7,768 |
| Alphagan PBrimonidine Tartrate | 23 | $6,333 |
| Travoprost | 31 | $5,976 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $803 | $141,954171 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $1,431 | $86,87588 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $222 | $41,96862 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $408 | $23,54426 claims |
| AlconSimbrinza | $2,604 | $7,76824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Tallmadge
- Todd BeyerTallmadge$20K
- Peter KaiserCleveland$1.5M
- Gregory EippertMentor$813K
- Robert OsherCincinnati$720K
- Justis EhlersCleveland$639K
- Lawrence SingermanBeachwood$599K
- Darrell WhiteWestlake$587K
- Alice EpitropoulosColumbus$531K
- Amy MillerDayton$526K
- Sunil SrivastavaCleveland$508K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.